Eric Lefkofsky is an active businessman, serial entrepreneur, and philanthropist. Over the past couple of years at the forefront of his focus has been one of his latest companies that he co-founded a couple of years ago.The business is called Tempus and t is a technology company that has started working in biotechnology.
Tempus is a business that aims to bring the future of medicine closer to the present. The company is focused on data-enable precision in medicine that is said to be the next step for the field. To be more specific, Tempus analyzes two types of data- molecular and clinical. Each set of data is specific to a patient with some kind of cancer, and Tempus aims to provide each case with a personalized therapy treatment to combat the disease as efficiently as possible. Tempus wants to transform the way cancer therapies are delivered.
Over its work, Tempus has had several hurdles such as expenses and the way personal data is collected about patients. Tempus has had to create software to read the hand-written notes that doctors had to provide as that is the most common way of collecting patient data. With the help of the software, Tempus has been able to collect and keep all of the information in a structured and accessible way.
Tempus uses a procedure called genome sequencing. The company had some problems at first as this process is extremely pricey. Now, it costs 5 000 dollars, but in 2003 it was at the mind-blowing cost of 100 million. Eric Lefkofsky and Tempus aim to bring down the price a bit further so that the genome sequencing can be used on a wider scale.
All in all, the work at Tempus has been going progressively forward despite the hurdles. The company has a number of partners such as universities, clinics, and hospitals around the United States of America. Some of the partners working with Tempus are the University of Michigan, the local University of Chicago- Medical School, the northwestern Lurie Cancer Center, the Mayo Clinic, and Penn’s Abramson Cancer Center, to name a few.